CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Walvax Biotechnology Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Walvax Biotechnology Co Ltd
No. 395, Kexin Road, High-tech Zone
Phone: +86 87168312779p:+86 87168312779 KUNMING, YUN  650101  China Ticker: 300142300142
Business Summary
Walvax Biotechnology Co Ltd is a China-based company primarily engaged in the research, development, production, and sales of human vaccines. The Company operates through Production segment, research and development segment, Industrial Investment segment, and Sales segment. The Company's products include the 13-valent pneumococcal conjugate vaccine (vial and pre-filled syringe), bivalent human papillomavirus (HPV) vaccine (vial and pre-filled syringe), 23-valent pneumococcal polysaccharide vaccine (vial and pre-filled syringe), Haemophilus influenzae type b conjugate vaccine (vial and pre-filled syringe), meningococcal polysaccharide conjugate vaccine for groups A and C (vial and pre-filled syringe), meningococcal polysaccharide vaccine for groups ACYW135 (vial and pre-filled syringe), meningococcal polysaccharide vaccine for groups A and C (vial), and adsorbed acellular pertussis, diphtheria, and tetanus combined vaccine (vial).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
5122 Drugs, drug proprietaries, and druggists' sundries
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Acting Secretary of the Board YunchunLi 63 6/16/2025 6/23/2009
President, Staff Elected Director WeiYao 53 7/8/2024 8/12/2016
Vice Chairman of the Board ShaozhongDong 57 8/5/2024 1/27/2022
10 additional Officers and Directors records available in full report.

Business Names
Business Name
300142
Walvax Biotechnology Co Ltd

General Information
Number of Employees: 1,932 (As of 12/31/2024)
Outstanding Shares: 1,599,348,541 (As of 9/30/2025)
Shareholders: 115,243
Stock Exchange: SHE
Fax Number: +86 87168312779


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 7, 2025